1620-77-5Relevant articles and documents
Compounds with Bridgehead Nitrogen
Crabb, Trevor A.,Heywood, Geoffrey C.
, p. 242 - 248 (1982)
The position of conformational equilibra in 1,5-,1,6- and 1,8-dimethylperhydro-oxazolopyridines were determined by 1H NMR spectroscopy.The cis-(H-5,H-8a)-1,5-dimethylperhydro-oxazolopyridines adopted the trans fused conformation, as did the two isomers of cis-(H-1,H-8a)-1,6-dimethyl-perhydro-oxazolopyridine.In contrast, r-1,t-6,t-8a-1,6-dimethyl-perhydro-oxazolopyridine preferred the cis-fused conformation.Three of the 1,8-dimehylperhdro-oxazolopyridines adopted the trans-fused conformations (with distortion of the system in the case of the r-1,c-8,c-8a derivative) and the r-1,c-8,c-8a-1,8-dimethyl derivative adopted the cis-fused conformation.
NOVEL PYRIDINE DERIVATIVES
-
Page/Page column 44, (2013/02/27)
The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
-
Page/Page column 41-42, (2012/10/08)
The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.